De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.

Subhamoy Chakraborty Charles Coleman Parvathy Manoj Deniz Demircioglu Nisargbhai S Shah Elisa de Stanchina Charles M Rudin Dan Hasson Triparna Sen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our study provides a mechanistic insight into lurbinectedin response in SCLC and the first demonstration that lurbinectedin is a potential therapeutic target after SCLC transformation.

Keyphrases

small cell lung cancer
epithelial mesenchymal transition
signaling pathway
pi k akt
brain metastases
oxidative stress
risk assessment